AMA Urges Federal Standards for Cannabis, Kratom, Seeks 'Special Schedule'

AMA Draws a Line at the Approval Pathway

The AMA wants botanical products, cannabis included, to clear the same safety and efficacy bar as any other drug.

According to Marijuana Moment, the AMA is urging federal officials to uphold "known and widely accepted scientific and clinical standards for testing safety and efficacy" for botanical drug products. The group named cannabis and kratom and referred to other plant-derived substances.

It also warned that political and commercial interests shouldn't circumvent the standard approval process. That's a pointed phrase. It reads as a shot at products and policies that outran the clinical evidence, though the summary available to CannIntel doesn't name a target.

A 'Special Schedule' for Research

The AMA's counterweight to its warning is a proposed "special schedule" meant to support research on these substances.

Marijuana Moment's reporting says the AMA believes such a schedule should be developed. The idea cuts against a common assumption that a physician group wary of botanicals would simply defend the status quo. Here, the AMA appears to argue the opposite: tight evidentiary standards and easier research access belong together.

In the AMA's framing, as reported, the road to legitimacy for botanical drugs runs through clinical trials rather than legislatures or marketing departments, and researchers need legal room to run them.

Details matter here. They're missing. Which agency would create the schedule, what criteria would govern placement, and how it would interact with existing Controlled Substances Act categories weren't in the material reviewed.

What the Record Doesn't Yet Show

The filing venue, the intended recipient agency and the proposed schedule's terms haven't been verified from the AMA's own document.

CannIntel's account rests on Marijuana Moment's published summary, which was posted Nov. 2, 2026. We haven't reviewed the AMA's text. Until we do, the precise language, date and addressee of the AMA's submission remain unconfirmed.

The institutional stakes are clear enough. Scheduling decisions under the Controlled Substances Act run through the DEA, with scientific and medical evaluation from the Department of Health and Human Services. A new research-oriented category would require both to move, and neither has signaled it will, based on the record reviewed.

For full background on this story, see the CannIntel topic hub on Federal Cannabis Research And Scheduling Policy.

The next signal: the AMA's full text. Whether it defines the special schedule's criteria, or only endorses the concept, will determine if this is policy or posture.